Biocon signs agreement for generic Ozempic commercialisation in Brazil with Biomm
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market
Biocon announced the signing of an exclusive licensing and supply agreement with Biomm, a speciality pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market.
Biomm is Brazil’s first and only biotechnology-focussed company, providing high-quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments. The Company focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their state-of-the-art production facility in Nova Lima.
Siddharth Mittal, CEO and MD, Biocon said, “Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the U.S. and Europe for Peptides. This is also in line with our growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products. We are confident that our collaboration with Biomm will provide patients in Brazil, who are living with diabetes, much-needed access to advanced, high-quality treatment options to help them manage the disease better.”
Heraldo Marchezini, CEO, Biomm, commented, “Brazil is the fifth country in the world with the highest incidence of diabetes, having 16.8 million adults in the age group of 20 to 79 years with the disease, and an estimated 21.5 million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF). We have, therefore, prioritised strategic partnerships to expand the population’s access to advanced treatments for this disease and enhance the quality of life for people.”
